Written Exposure Therapy Plus Adjunctive Methylphenidate Treatment for Veterans With PTSD

Ki vehet részt

• Veteran
• Current post-traumatic stress disorder (PTSD) symptoms
• Medically healthy
• Body weight of ≥ 120 pounds (55 kilograms)
• Participants must be able to participate and willing to give written informed consent and to comply with the study restrictions

Ki nem vehet részt

• Unable to abstain from alcohol the evening before or day of study drug administration
• Drugs of abuse as determined by a positive urine test, excepting THC
• Current use of any psychotropic medication that has not been at a stable dose
• Current or recent use of a monoamine oxidase inhibitor or any other medication deemed by the study physician to exhibit an unsafe interaction with methylphenidate (MPH)
• Participation in a clinical trial with an investigational drug or a device within 30 days prior to dosing
• Concurrent participation in an evidence-based behavioral therapy treatment for PTSD
• Medical conditions that could alter the absorption, metabolism or elimination of study drug
• Family history of sudden death or ventricular arrhythmia
• History of glaucoma
• History, including family history, of motor tic or diagnosis of Tourette's syndrome
• Lifetime history of a chronic psychotic disorder or bipolar disorder type I
• Lifetime history of stimulant use disorder
• Current moderate or severe substance use disorder for any other substances
• History of a traumatic brain injury (TBI) resulting in loss of consciousness for more than 30 minutes
• Current uncontrolled hypertension
• Major medical issues
• Pregnancy or lactation
• High suicidal risk
• Marked anxiety, tension, or agitation, based on clinical observation, that is not due to an outside identifiable, transient, or modifiable cause
• Past intolerance to methylphenidate (MPH) or any other psychostimulant
• Current heavy smoker and/or heavy caffeine consumption and unable to limit on study days
• Abnormal Electrocardiogram, per study physician
• Volunteers who are unable to understand the informed consent form(s) and complete the study procedures including clinical testing
• Any other reason, per study investigators, that would put the participant at undue risk or interfere with the conduct of the study per protocol